These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 37544825)

  • 1. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
    Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
    Vaccine; 2023 Aug; 41(38):5662-5669. PubMed ID: 37544825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.
    Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
    Clin Infect Dis; 2023 Feb; 76(3):e1062-e1070. PubMed ID: 35789262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
    Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
    PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination-A longitudinal study over 10 years based on public surveillance data in the Nordics.
    Palmborg A; Skovdal M; Molden T; Åhman H; Chen L; Banefelt J
    PLoS One; 2023; 18(6):e0287378. PubMed ID: 37363884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
    Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
    Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
    Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
    Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study.
    Choi YH; Bertran M; Litt DJ; Ladhani SN; Miller E
    Lancet Public Health; 2024 Sep; 9(9):e654-e663. PubMed ID: 39153492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.
    Balsells E; Guillot L; Nair H; Kyaw MH
    PLoS One; 2017; 12(5):e0177113. PubMed ID: 28486544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
    Amin-Chowdhury Z; Groves N; Sheppard CL; Litt D; Fry NK; Andrews N; Ladhani SN
    Vaccine; 2021 Apr; 39(14):1997-2004. PubMed ID: 33715901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era.
    de Miguel S; Domenech M; González-Camacho F; Sempere J; Vicioso D; Sanz JC; Comas LG; Ardanuy C; Fenoll A; Yuste J
    Clin Infect Dis; 2021 Dec; 73(11):e3778-e3787. PubMed ID: 32990303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
    Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L
    Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20.
    Schellenberg JJ; Adam HJ; Baxter MR; Karlowsky JA; Golden AR; Martin I; Demczuk W; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2023 May; 78(Suppl 1):i37-i47. PubMed ID: 37130588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age.
    Wasserman MD; Perdrizet J; Grant L; Hayford K; Singh S; Saharia P; Horn EK; Farkouh RA
    Infect Dis Ther; 2021 Dec; 10(4):2701-2720. PubMed ID: 34633639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen.
    Ryman J; Sachs JR; Banniettis N; Weiss T; Ahsman M; Yee KL; Weaver J
    Expert Rev Vaccines; 2024; 23(1):467-473. PubMed ID: 38546743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.